138 related articles for article (PubMed ID: 17141198)
1. Identification of a novel competitive inhibitor of p38alpha MAPK by a human PBMC screen.
Liu YC; Ko CC; Cheng FC; Huang PT; Lou KL; Chow LP
Biochem Biophys Res Commun; 2007 Jan; 352(3):656-61. PubMed ID: 17141198
[TBL] [Abstract][Full Text] [Related]
2. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood.
Hochart H; Jenkins PV; Preston RJ; Smith OP; White B; O'Donnell J
Thromb Haemost; 2008 Mar; 99(3):570-5. PubMed ID: 18327406
[TBL] [Abstract][Full Text] [Related]
3. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
5. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
[TBL] [Abstract][Full Text] [Related]
6. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
[TBL] [Abstract][Full Text] [Related]
7. Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases.
Kjellerup RB; Kragballe K; Iversen L; Johansen C
Exp Dermatol; 2008 Jun; 17(6):498-504. PubMed ID: 18081851
[TBL] [Abstract][Full Text] [Related]
8. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
9. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
10. The multicomponent phytopharmaceutical SKI306X inhibits in vitro cartilage degradation and the production of inflammatory mediators.
Hartog A; Hougee S; Faber J; Sanders A; Zuurman C; Smit HF; van der Kraan PM; Hoijer MA; Garssen J
Phytomedicine; 2008 May; 15(5):313-20. PubMed ID: 17949960
[TBL] [Abstract][Full Text] [Related]
11. Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells.
Monagas M; Khan N; Andrés-Lacueva C; Urpí-Sardá M; Vázquez-Agell M; Lamuela-Raventós RM; Estruch R
Br J Nutr; 2009 Jul; 102(2):201-6. PubMed ID: 19586571
[TBL] [Abstract][Full Text] [Related]
12. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes.
Xu H; He Y; Yang X; Liang L; Zhan Z; Ye Y; Yang X; Lian F; Sun L
Rheumatology (Oxford); 2007 Jun; 46(6):920-6. PubMed ID: 17314215
[TBL] [Abstract][Full Text] [Related]
13. Flower extract of Panax notoginseng attenuates lipopolysaccharide-induced inflammatory response via blocking of NF-kappaB signaling pathway in murine macrophages.
Jung HW; Seo UK; Kim JH; Leem KH; Park YK
J Ethnopharmacol; 2009 Mar; 122(2):313-9. PubMed ID: 19162159
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
[TBL] [Abstract][Full Text] [Related]
17. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
19. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
Peifer C; Urich R; Schattel V; Abadleh M; Röttig M; Kohlbacher O; Laufer S
Bioorg Med Chem Lett; 2008 Feb; 18(4):1431-5. PubMed ID: 18207396
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors.
Dorn A; Schattel V; Laufer S
Bioorg Med Chem Lett; 2010 May; 20(10):3074-7. PubMed ID: 20418099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
